AIMS AND SCOPE

Psychiatry and Clinical Psychopharmacology (formerly Bulletin of Clinical Psychopharmacology 1996-2016) is an international, scientific, open access, online-only periodical published in accordance with independent, unbiased, and double-blinded peer-review principles. The journal is published quarterly in March, June, September, and December. The publication language of the journal is American English.

The aim of the journal is to bridge the gap between basic and clinical application by publishing high quality research in psychiatry and clinical psychopharmacology. The scope of the journal includes but not limited to psychiatry, child and adolescent psychiatry, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, neuroimaging, artificial intelligence, machine learning, neuronal networks, and related sciences. Psychiatry and Clinical Psychopharmacology accepts research articles, reviews, case reports, letters to the editors, editorials, and short communications/brief reports.

The target audience of the journal includes specialists, residents, and scientists in psychiatry, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, and related disciplines.

Psychiatry and Clinical Psychopharmacology is currently indexed in Science Citation Index Expanded, Scopus, Embase, HINARI, Proquest: Proquest Psychology Journals, Proquest Health & Medical Complete, PsychINFO, PsycSCAN: Psychopharmacology, EBSCO, and Chemical Abstracts (CAS).

The editorial and publication processes of the journal are shaped in accordance with the guidelines of the International Committee of Medical Journal Editors (ICMJE), World Association of Medical Editors (WAME), Council of Science Editors (CSE), Committee on Publication Ethics (COPE), European Association of Science Editors (EASE), and National Information Standards Organization (NISO). The journal is in conformity with the Principles of Transparency and Best Practice in Scholarly Publishing (doaj.org/bestpractice).

Publication Fee Policy
Authors should pay a one-time article processing charge (APC) to cover the costs of peer review administration and management, production of articles in PDF and to other publishing functions. There are no surcharges based on the length of an article, figures or supplementary data. In order to cover publication costs, the standard APC for Psychiatry and Clinical Psychopharmacology is $590 (including taxes).

Please note that all submissions are evaluated by the Editorial Board and external reviewers in terms of scientific quality and ethical standards. APC payments have no effect on the outcome of the article's evaluation and/or publication priority.

Account holder name: 26688848 - AVES Yayincilik Ltd. Sti.
Bank name: Halkbank/Gayrettepe
Account: 0850 53870964
IBAN no: TR19 0001 2009 8500 0053 8709 64

Advertisement Policy
Psychiatry and Clinical Psychopharmacology can publish advertisement images in the journal's website upon the approval of the Editor in Chief. Potential advertisers should contact the Editorial Office. Advertisers have no effect on the editorial decisions or advertising policies.

Disclaimer
Statements or opinions expressed in the manuscripts published in the journal reflect the views of the author(s) and not the opinions of the editors, editorial board, and/or publisher; the editors, editorial board, and publisher disclaim any responsibility or liability for such materials.

Open Access Statement
Psychiatry and Clinical Psychopharmacology is an open access publication, and the journal's publication model is based on Budapest Access Initiative (BOAI) declaration. All published content is available online, free of charge at www.psychiatry-psychopharmacology.com. The journal's content is licensed under a Creative Commons Attribution-NonCommercial (CC BY-NC) 4.0 International License which permits third parties to share and adapt the content for non-commercial purposes by giving the appropriate credit to the original work.

Editor in Chief: Mesut Cetin, M.D., Professor of Psychiatry
Address: Bagdat Caddesi Birgen Plaza 226/7 Kadikoy 34728 Istanbul, Turkey
Mobile & Whatsapp: +90-532-272-3252
psikofarmakoloji@gmail.com

Publisher: AVES
Address: Büyükderece Cad., 105/9 34394 Şişli, İstanbul, Turkey
Phone: +90 212 217 17 00
E-mail address: info@avesyayincilik.com
www.avesyayincilik.com
INSTRUCTIONS TO AUTHORS

Psychiatry and Clinical Psychopharmacology (formerly Bulletin of Clinical Psychopharmacology 1996-2016) is an international, scientific, open access, online-only periodical published in accordance with independent, unbiased, and double-blinded peer-review principles. The journal is published quarterly in March, June, September, and December. The publication language of the journal is English (US).

The aim of the journal is to bridge the gap between basic and clinical application by publishing high quality research in psychiatry and clinical psychopharmacology. The scope of the journal includes but not limited to psychiatry, child and adolescent psychiatry, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, neuroimaging, artificial intelligence, machine learning, neuronal networks, and related sciences.

Psychiatry and Clinical Psychopharmacology accepts research articles, reviews, case reports, letters to the editors, editorials, and short communications/brief reports.

The target audience of the journal includes specialists, residents, and scientists in psychiatry, psychology, neurology, pharmacology, molecular biology, genetics, physiology, neurochemistry, and related disciplines.

EDITORIAL AND PUBLICATION PROCESS

The editorial and publication processes of the journal are shaped in accordance with the guidelines of the International Council of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), the Council of Science Editors (CSE), the Committee on Publication Ethics (COPE), the European Association of Science Editors (EASE), and National Information Standards Organization (NISO). The journal conforms to the Principles of Transparency and Best Practice in Scholarly Publishing (doaj.org/bestpractice).

Originality, high scientific quality, and citation potential are the most important criteria for a manuscript to be accepted for publication. Manuscripts submitted for evaluation should not have been previously presented or already published in an electronic or printed medium. The journal should be informed of manuscripts that have been submitted to another journal for evaluation and rejected for publication. The submission of previous reviewer reports will expedite the evaluation process. Manuscripts that have been presented in a meeting should be submitted with detailed information on the organization, including the name, date, and location of the organization.

PEER REVIEW PROCESS

Manuscripts submitted to Psychiatry and Clinical Psychopharmacology will go through a double-blind peer-review process. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in their fields in order to ensure an unbiased evaluation process. The editorial board will invite an external and independent editor to manage the evaluation processes of manuscripts submitted by editors or by the editorial board members of the journal. The Editor in Chief is the final authority in the decision-making process for all submissions.

ETHICAL GUIDELINES

An approval of research protocols by the Ethics Committee in accordance with international agreements (World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects, amended in October 2013, www.wma.net) is required for experimental, clinical, and drug studies and for some case reports. If required, ethics committee reports, or an equivalent official document will be requested from the authors. Submissions which do not have ethical approval will be reviewed according to COPE’s Research, Audit and Service Evaluations guideline.

Such manuscripts can be rejected after editorial review due to the lack of ethics committee approval.

For manuscripts concerning experimental research on humans, a statement should be included that written informed consent of patients and volunteers was obtained following a detailed explanation of the procedures that they may undergo.

It is the authors’ responsibility to protect the patients’ anonymity carefully. For photographs that may reveal the identity of the patients, signed releases of the patient or their legal representative should be enclosed, and the publication approval must be provided in the Methods section.

For studies carried out on animals, an approval research protocols by the Ethics Committee in accordance with international agreements (Guide for the care and use of laboratory animals, 8th edition, 2011” and/or “International Guiding Principles for Biomedical Research Involving Animals, 2012”) is required. Also, the measures taken to prevent pain and suffering of the animals should be stated clearly in such studies.

Information on patient consent, the name of the ethics committee, and the ethics committee approval number and date should also be stated in the Methods section of the manuscript.

PLAGIARISM AND ETHICAL MISCONDUCT

Psychiatry and Clinical Psychopharmacology is extremely sensitive about plagiarism. All submissions are screened by a similarity detection software (iThenticate by CrossCheck) at any point during the peer-review and/or production process.

When you are discussing others’ (or your own) previous work, please make sure that you cite the material correctly in every instance.

Authors are strongly recommended to avoid any form of plagiarism and ethical misconduct that are exemplified below.

Self-plagiarism (text-recycling): Overlapping sections or sentences with the author’s previous publications without citing them. Even if you are the author of the phrases or sentences, the text should not have unacceptable similarity with the previously published data.

Salami slicing: Using the same data of a research into several different articles. Reporting the same hypotheses, population, and methods of a study is into different papers is not acceptable.

Data Fabrication: It is the addition of data that never occurred during the gathering of data or the experiments. Results and their interpretation must be based on the complete data sets and reported accordingly.

Data Manipulation/Falsification: It means manipulating research data with the intention of giving a false impression. This includes manipulating images (e.g. micrographs, gels, radiological images), removing outliers or ‘inconvenient’ results, changing data points, etc.

In the event of alleged or suspected research misconduct, e.g., plagiarism, citation manipulation, and data falsification/fabrication, the Editorial Board will follow and act according to COPE flowcharts.

PREPRINT

Psychiatry and Clinical Psychopharmacology does not consider preprint publications as prior publication. In other words, authors are allowed to present and discuss their findings on a non-commercial preprint server before submission to a journal.

Authors must provide the journal with the pre-print server deposition of their article accompanying its DOI during initial submission.
If the article is published in the Psychiatry and Clinical Psychopharmacology, it is the responsibility of the authors to update the archived preprint and link it to the published version of the article.

AUTHORSHIP

Each person listed as an author should fulfill the authorship criteria recommended by the International Committee of Medical Journal Editors (ICMJE - www.icmje.org). The ICMJE recommends that authorship is based on the following four criteria:

1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

In addition to being accountable for the parts of the work he/she has done, an author should be able to identify which co-authors are responsible for specific parts of the work. Also, authors should have confidence in the integrity of the contributions of their co-authors.

All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged in the title page of the manuscript.

Psychiatry and Clinical Psychopharmacology requires corresponding authors to submit a signed and scanned version of the Copyright Agreement and Acknowledgement of Authorship form (available for download www.psychiatry-psychopharmacology.com) during the initial submission process to act appropriately on authorship rights and to prevent ghost or honorary authorship. If the editorial board suspects a case of "gift authorship," the submission will be rejected without further review. As part of the submission of the manuscript, the corresponding author should also send a short statement declaring that he/she accepts to undertake all the responsibility for authorship during the submission and review stages of the manuscript.

CHANGE OF AUTHORSHIP

Psychiatry and Clinical Psychopharmacology reviews the authorship according to the author's declaration in the Title Page, thus it is the authors responsibility to send the final order of the complete author names. Requests in the change of authorship (e.g. removal/addition of the authors, change in the order etc.) after submission are subject to editorial approval. Editorial Board will investigate this kind of cases and act followingCOPE flowcharts.

Change of authorship requests should be submitted to the Editorial Office with an official letter stating the reasons of the change. The letter must be signed by all authors and include their approval on the change in authorship. If the request is approved by the Editorial Board, authors need to submit a new Copyright Agreement Form according to the final order list.

DECLARATION OF INTEREST

Psychiatry and Clinical Psychopharmacology requires and encourages the authors and the individuals involved in the evaluation process of submitted manuscripts to disclose any existing or potential conflicts of interests, including financial, consultative, and institutional, that might lead to potential bias or a conflict of interest. Any financial grants or other support received for a submitted study from individuals or institutions should be disclosed to the Editorial Board. To disclose a potential conflict of interest, the ICMJE Potential Conflict of Interest Disclosure Form should be filled in and submitted by all contributing authors. The journal's Editorial Board resolves cases of a potential conflict of interest of the editors, authors, or reviewers within the scope of COPE and ICMJE guidelines.

APPEALS AND COMPLAINT

The Editorial Board of the journal handles all appeal and complaint cases within the scope of COPE guidelines. In such cases, authors should get in direct contact with the editorial office regarding their appeals and complaints. When needed, an ombudsperson may be assigned to resolve claims that cannot be resolved internally. The Editor in Chief is the final authority in the decision-making process for all appeals and complaints.

COPYRIGHT AND LICENSE

Psychiatry and Clinical Psychopharmacology requires each submission to be accompanied by a Copyright Agreement and Acknowledgement of Authorship form (available for download www.psychiatry-psychopharmacology.com). By signing this form, authors retain the copyright of their work and agree that the article, if accepted for publication by the Psychiatry and Clinical Psychopharmacology will be licensed under a Creative Commons Attribution-NonCommercial (CC BY-NC) 4.0 International License which permits third parties to share and adapt the content for non-commercial purposes by giving the appropriate credit to the original work.

When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s).

DISCLAIMER

Statements or opinions expressed in the manuscripts published in Psychiatry and Clinical Psychopharmacology reflect the views of the author(s) and not the opinions of the editors, the editorial board, or the publisher; the editors, the editorial board, and the publisher disclaim any responsibility or liability for such materials. The final responsibility regarding the published content rests with the authors.

MANUSCRIPT PREPARATION

The manuscripts should be prepared in accordance with ICMJE-Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (updated in December 2018 - http://www.icmje.org/icmje-recommendations.pdf). Authors are required to prepare manuscripts in accordance with the CONSORT guidelines for randomized research studies, STROBE guidelines for observational original research studies, STARD guidelines for studies on diagnostic accuracy, PRISMA guidelines for systematic reviews and meta-analysis, ARRIVE guidelines for experimental animal studies, and TREND guidelines for non-randomized public behavior. The style of the manuscripts should be prepared according to AMA Manual of Style 11th Edition.

Manuscripts can only be submitted through the journal's online manuscript submission and evaluation system, available at pcp.manuscriptmanager.net. Manuscripts submitted via any other medium and submissions by anyone other than one of the authors will not be evaluated.

Manuscripts submitted to the journal will first go through a technical evaluation process where the editorial office staff will ensure that the manuscript has been prepared and submitted in accordance with the journal's guidelines. Submissions that do not conform to the journal's guidelines will be returned to the submitting author with technical correction requests.

Authors are required to submit the following:

- Copyright Agreement and Acknowledgement of Authorship Form, and
- ICMJE Potential Conflict of Interest Disclosure Form (should be filled in by all contributing authors) during the initial submission. These forms are available for download at www.psychiatry-psychopharmacology.com.
Preparation of the Manuscript

Title page: A separate title page should be submitted with all submissions and this page should include:

- The full title of the manuscript as well as a short title (running head) of no more than 50 characters,
- Name(s), affiliations, highest academic degree(s), and ORCID IDs of the author(s),
- Grant information and detailed information on the other sources of support,
- Name, address, telephone (including the mobile phone number), and email address of the corresponding author,
- Acknowledgment of the individuals who contributed to the preparation of the manuscript but who do not fulfill the authorship criteria.

Abstract: An abstract should be submitted with all submissions except for Letters to the Editor. The abstract of Research Articles should be structured with subsections (Background, Methods, Results, and Conclusion). Please check Table 1 below for word count specifications.

Keywords: Each submission must be accompanied by a minimum of three to a maximum of five keywords for subject indexing at the end of the abstract. The keywords should be listed in full without abbreviations. The keywords should be selected from the National Library of Medicine, Medical Subject Headings database (https://www.nlm.nih.gov/mesh/MBrowser.html).

Main Points: All submissions except letters to the editor should be accompanied by 3 to 5 "main points" which should emphasize the most noteworthy results of the study and underline the principal message that is addressed to the reader. This section should be structured as itemized to give a general overview of the article. Since "Main Points" targeting the experts and specialists of the field, each item should be written as plain and straightforward as possible.

Manuscript Types
Research Articles: This is the most important type of article since it provides new information based on original research. Acceptance of original papers will be based upon the originality and importance of the investigation. The main text of original articles should be structured with Introduction, Material and Methods, Results, and Discussion subsections. Please check Table 1 for the limitations for Original Articles.

Clinical Trials
Psychiatry and Clinical Psychopharmacology accepts the ICMJE’s clinical trial registration policy, which requires that clinical trials must be registered in a publicly accessible registry that is a primary register of the WHO International Clinical Trials Registry Platform (ICTRP) or in ClinicalTrials.gov.

Instructions for the clinical trials are listed below:

- Clinical trial registry is only required for the prospective research projects that study the relationship between a health-related intervention and an outcome by assigning people.
- To have their manuscript evaluated in the journal, authors should register their research to a public registry at or before the time of first patient enrollment.
- Based on most up to date ICMJE recommendations, Psychiatry and Clinical Psychopharmacology accepts public registries that include minimum acceptable 24-item trial registration dataset.
- Authors are required to state a data sharing plan for the clinical trial in the "Data Sharing" section.
- For further details, please check ICMJE Clinical Trial Policy at https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html

Data Sharing
As of 1 January 2019, a data sharing statement is required for the registration of clinical trials. Authors are required to provide a data sharing statement for the articles that reports the results of a clinical trial. The data sharing statement should indicate the items below according to the ICMJE data sharing policy:

- Whether individual deidentified participant data will be shared
- What data in particular will be shared
- Whether additional, related documents will be available
- When the data will be available and for how long
- By what access criteria will be shared

Authors are recommended to check the ICMJE data sharing examples at http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html

While submitting a clinical trial to Psychiatry and Clinical Psychopharmacology:

- Authors are required to make registration to a publicly accessible registry according to ICMJE recommendations and the instructions above.
- The name of the registry and the registration number should be provided in the Title Page during the initial submission.
- Data sharing statement should also be stated in the Title Page even the authors do not plan to share it.

Clinical trial and data sharing policy of the journal will be valid for the articles submitted from 1 March 2021.

Reporting Statistical Analysis

Information on statistical analyses should be provided with a separate subheading under the Materials and Methods section and the statistical software that was used during the process must be specified.

Values for reporting statistical data, such as P values and CIs should be presented and rounded appropriately. P values should be expressed as 2 digits to the right of the decimal point unless the first 2 digits are zeros, in which case 3 digits to the right of the decimal place should be provided (eg, instead of P = .002). However, values close to .05 may be reported to 3 decimal places because the .05 is an arbitrary cut point for statistical significance (eg, P = .053). P values less than .001 should be designated as P < .001 rather than exact values (eg, P = .000006).

Units should be prepared in accordance with the International System of Units (SI).

Editorial Comments: Invited brief editorial comments on selected articles are published in the Psychiatry and Clinical Psychopharmacology. Editorials should not be longer than 1000 words excluding references. Editorial comments aim to provide a brief critical commentary by reviewers with expertise or with high reputation in the topic of the research article published in the journal. Authors are selected and invited by the journal to provide such comments. Abstracts, Keywords, and Tables, Figures, Images, and other media are not included.

Review Articles: Reviews prepared by authors who have extensive knowledge on a particular field and whose scientific background has been translated into a high volume of publications with high citation potential are welcomed. These authors may even be invited by the journal. Reviews should describe, discuss, and evaluate the current level of knowledge of a topic in clinical practice and should guide future studies. The subheadings of the review articles should be planned by the authors. However, each review article should include an “Introduction” and a “Conclusion” section. Please check Table 1 for the limitations for Review Articles.
The manuscript should be blind. The minimum resolution of each submitted figure should be clear in resolution and large in size (minimum 300 DPI). Each image should be submitted separately through the submission system. Images should not be labeled (a, b, c, etc.) to indicate figure subunits. Thick and thin arrows, arrowheads, stars, asterisks, and similar marks can be used on the images to support figure legends. Like figure subunits, the subunits should not be merged to form a single image. Each subunit should be submitted separately through the submission system. Images should not be labeled (a, b, c, etc.) to indicate figure subunits. Thick and thin arrows, arrowheads, stars, asterisks, and similar marks can be used on the images to support figure legends. Like the rest of the submission, the figures too should be blind. Any information within the images that may indicate an individual or institution should be blinded. The minimum resolution of each submitted figure should be 300 DPI. To prevent delays in the evaluation process, all submitted figures should be clear in resolution and large in size (minimum dimensions: 100 × 100 mm). Figure legends should be listed at the end of the main document.

All acronyms and abbreviations used in the manuscript should be defined at first use, both in the abstract and in the main text. The abbreviation should be provided in parentheses following the definition. When a drug, product, hardware, or software program is mentioned within the main text, product information, including the name of the producer, the producer of the product, and city and the country of the company (including the state if in USA), should be provided in parentheses in the following format: "Discovery St PET/CT scanner (General Electric, Milwaukee, WI, USA)"

All references, tables, and figures should be referred to within the main text, and they should be numbered consecutively in the order they are referred to within the main text.

Limitations, drawbacks, and the shortcomings of original articles should be mentioned in the Discussion section before the conclusion paragraph.

References
Both in-text citations and the references must be prepared according to the AMA Manual of Style 11th Edition. While citing publications, reference should be given to the latest, most up-to-date publications. Authors are responsible for the accuracy of references. If an ahead-of-print publication is cited, the DOI number should be provided. Journal titles should be abbreviated in accordance with the journal abbreviations in Index Medicus/MEDLINE/PubMed. When there are six or fewer authors, all authors should be listed. If there are seven or more authors, the first three authors should be listed followed by “et al.” In the main text of the manuscript, references should be cited in superscript after punctuation. The reference styles for different types of publications are presented in the following examples.


Table 1. Limitations for each manuscript type

<table>
<thead>
<tr>
<th>Type of manuscript</th>
<th>Word limit* (Min-Max)</th>
<th>Abstract Word limit</th>
<th>Reference limit</th>
<th>Table limit</th>
<th>Figure limit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original Article</td>
<td>3500-5000</td>
<td>200-250 (Structured)</td>
<td>30</td>
<td>6</td>
<td>7 or total of 10 images</td>
</tr>
<tr>
<td>Review Article</td>
<td>4000-6000</td>
<td>200-250</td>
<td>50</td>
<td>6</td>
<td>10 or total of 15 images</td>
</tr>
<tr>
<td>Case Report</td>
<td>1000-2000</td>
<td>100-150</td>
<td>15</td>
<td>No tables</td>
<td>1 or total of 3 images</td>
</tr>
<tr>
<td>Brief Report</td>
<td>2500</td>
<td>200-250</td>
<td>20</td>
<td>6</td>
<td>5 or total of 10 images</td>
</tr>
<tr>
<td>Letter to the Editor</td>
<td>500-1000</td>
<td>No abstract</td>
<td>5</td>
<td>No tables</td>
<td>No figures</td>
</tr>
<tr>
<td>Editorial</td>
<td>1500-3000</td>
<td>No abstract</td>
<td>20</td>
<td>5</td>
<td>5 or total of 10 images</td>
</tr>
</tbody>
</table>

*Word limit should not include the abstract, references, tables, and figure legends.


REVISIONS

When submitting a revised version of a paper, the author must submit a detailed “Response to the reviewers” that states point by point how each issue raised by the reviewers has been covered and where it can be found (each reviewer’s comment, followed by the author’s reply and line numbers where the changes have been made) as well as an annotated copy of the main document. Revised manuscripts must be submitted within 30 days from the date of the decision letter. If the revised version of the manuscript is not submitted within the allocated time, the revision option may be canceled. If the submitting author(s) believe that additional time is required, they should request this extension before the initial 30-day period is over.

Accepted manuscripts are copy-edited for grammar, punctuation, and format. Once the publication process of a manuscript is completed, it is published online on the journal’s webpage as an ahead-of-print publication before it is included in its scheduled issue. A PDF proof of the accepted manuscript is sent to the corresponding author and their publication approval is requested within 2 days of their receipt of the proof.

Editor in Chief: Mesut Cetin, M.D., Professor of Psychiatry
Address: Bagdat Caddesi Birgen Plaza 226/7 Kadikoy 34728 Istanbul TURKEY
Mobile & WhatsApp: +90-532-272-3252
E-mail address: psikofarmakoloji@gmail.com

Publisher: AVES
Address: Büyükderece Cad., 105/9 34394 Şişli, Istanbul TURKEY
Phone: +90 212 217 17 00
E-mail address: info@avesyayincilik.com
www.avesyayincilik.com
CONTENTS

ORIGINAL ARTICLE

245 Left Cerebral Cortex Complexity in Patients with Major Depression Disorder: A Small-Sample Pilot Study
Jian Liu, Xinying Chen, Chuanxin Liu, Min Chen, Deguo Jiang, Xiaodong Lin, Gongying Li, Hongjun Tian, Lina Wang, Chuanjun Zhao, Wenzhen Tu

252 Association of Glial Cell-Line Derived Neurotrophic Factor and Nerve Growth Factor with Duration of Untreated Psychosis and Clinical Symptoms in Drug-Naive Schizophrenia
Başıle Tıkır, Ömer Asan, Andaç Uzdoğan, Şafak Yalçın Şahiner, Erol GökÇa

261 Peripheral Expression of MACROD2 Gene Is Reduced Among a Sample of Turkish Children with Autism Spectrum Disorder
Alper Alnak, İpek Kuşcu Özücer, Ahmet Okay Çağlayan, Murat Coşkun

269 Unstructured Group Support Enhances Compliance to Pharmacological Treatment by Improving Social Cognition in Patients with Bipolar Disorder: A Pilot fMRI Study
Ying Wang, Yonghui Zhang, Hongjun Tian, Min Chen, Guandong Chen, Deguo Jiang, Ce Chen, Gongying Li, Chuanjun Zhao, Jianjing Zhang, Haoran Chen

280 Association of the Uncoupling Protein 2-866 G/A Polymorphism with Family History and Duration of Tobacco Use Disorder in a Turkish Population
Hasan Mervan Aytac, Sacide Pehlivan, Selin Kurnaz, Mustafa Pehlivan, Pınar Çetinay Aydın

286 Plasma Orexin Levels Related to Altered Brain Activity During Abstinence in Patients with Alcohol Dependence
Jianhe Pan, Guangdong Chen, Peiwei Shan, Ce Chen, Deguo Jiang, Lina Wang, Gongying Li, Min Chen, Chuanjun Zhao, Tao Fang, Haiqing Yu

292 A Way to Increase the Sensitivity and Specificity of the Hamilton Depression and Anxiety Scales
Mehmet Güven Günver, Mustafa Şenocak, Reyhan Ilhan, Hazal Aktaş, Sevgi Köşü, Özden Oksüz, Muhammed Taha Esmeray, Hamide Lacin, Mehmet Kemal Arıkan

303 The Associations Between Attachment, Thought-Action Fusion, and Anxiety in Adolescents: Mediator Effect of Thought-Action Fusion
Ezgi Şen Demirdöğen, Nihal Serdengeçti, İlayda Sevilmiş, Cağla Nane, Eda Soyoz, Mesut Yavuz

310 Development and Verification of Problematic Cryptocurrency Trading Scale
Nurettin Menteş, İlyas Yolbaş, Mahmut Bulat

319 Confirmatory Factor Analyses of the Turkish Version of the WISC-IV in Non-clinical Sample: Validation of the Wechsler and CHC Models with Core and Supplemental Subtests
Çiğdem Çeşik

331 COVID-19 Patient Care Leading to Occupational Burnout in Resident Doctors: A Follow-up Study
Ersin Yüksel, Akın Tahıllıoğlu, Sarp Gönenc Samancı, Şeyda Ceylan Artı, Kazım Koray Özgül, Eyyüp Sabri Erkan

339 Platelet Parameters in First-Episode Patients with Schizophrenia and Bipolar Disorder
Beşik Han Altüns, Oğuzcan Bekir Eğilmez

REVIEW ARTICLE

344 The Use of Tamoxifen as a Potential Treatment for Bipolar Disorder
Noy Bagdadi, Abed N. Azab, Rachel Shvartsur

SHORT COMMUNICATION

353 Copper and Impulsivity in Ketamine Treatment for Treatment-Resistant Mood Disorders
Jakub Słupski, Wiesław Jerzy Cubala, Natalia Görńska, Ania Słupska, Maria Gałuszko-Węgielnik

CASE REPORT

358 Oromandibular Dystonia Treatment With Aripiprazole in an Adolescent Patient 2-Year Follow-Up: A Case Report
Yusuf Yasin Gümüş, Gözde Nur Say